My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Volumes jump at Katwa Udyog counter
Nov 23,2016

Katwa Udyog clocked volume of 13.74 lakh shares by 13:24 IST on BSE, a 542.81-times surge over two-week average daily volume of 3,000 shares. The stock jumped 19.38% to Rs 93.

JK Lakshmi Cement notched up volume of 1.64 lakh shares, a 17.56-fold surge over two-week average daily volume of 9,000 shares. The stock rose 4.25% to Rs 361.80.

HPL Electric & Power saw volume of 17.46 lakh shares, a 15.42-fold surge over two-week average daily volume of 1.13 lakh shares. The stock rose 6.86% to Rs 87.25.

Sunil Hitech Engineers clocked volume of 31.02 lakh shares, a 12.58-fold surge over two-week average daily volume of 2.47 lakh shares. The stock dropped 4.28% to Rs 167.90.

Adani Transmission saw volume of 10.38 lakh shares, a 6.94-fold rise over two-week average daily volume of 1.50 lakh shares. The stock jumped 18.56% to Rs 55.25.

Powered by Capital Market - Live News

Cipla gains after UK arm divests stake in Chase Pharmaceuticals
Nov 23,2016

The announcement was made during trading hours today, 23 November 2016.

Meanwhile, the BSE Sensex was up 38.86 points, or 0.15%, to 25,999.64.

On BSE, so far 80,000 shares were traded in the counter, compared with average daily volume of 1.70 lakh shares in the past one quarter. The stock hit a high of Rs 559 and a low of Rs 547.85 so far during the day. The stock hit a 52-week high of Rs 660 on 29 December 2015. The stock hit a 52-week low of Rs 458.25 on 25 May 2016. The stock had outperformed the market over the past 30 days till 22 November 2016, falling 6.03% compared with the 7.87% decline in the Sensex. The scrip had also outperformed the market in past one quarter, falling 2.85% as against Sensexs 7.48% decline.

The large-cap company has equity capital of Rs 160.85 crore. Face value per share is Rs 2.

Cipla announced that Chase Pharmaceuticals Corporation, a Delaware based corporation (Chase) (in which Ciplas UK arm, Cipla (EU), (Cipla UK) has 16.7% stake) has been acquired by a subsidiary of Allergan, plc. Allergan has agreed to pay $125 million upfront plus potential regulatory and commercial milestones of up to $875 million to the shareholders of Chase. Cipla UK acquired a minority stake in Chase in May 2014 via a syndicated venture investment.

Chandru Chawla, Head of Corporate Strategy and Cipla New Ventures said, Cipla Group is proud to have made a meaningful contribution in advancing an Alzheimers drug to an advanced stage of development where the product has now successfully concluded Phase 2 study. Chases pipeline will be successful at Allergan, given their strength as a leading CNS commercial franchise, he added.

Chase Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders.

On a consolidated basis, Ciplas net profit dropped 34.75% to Rs 354.34 crore on 8.66% rise in net sales to Rs 3671.88 crore in Q2 September 2016 over Q2 September 2015.

Cipla is a global pharmaceutical company.

Powered by Capital Market - Live News

Lupin gains after tentative approval from USFDA for Epzicom generic
Nov 23,2016

The announcement was made during market hours today, 23 November 2016.

Meanwhile, the BSE Sensex was up 51.06 points, or 0.20%, to 26,011.84.

On BSE, so far 38,000 shares were traded in the counter, compared with average daily volume of 1.04 lakh shares in the past one quarter. The stock hit a high of Rs 1,447.90 and a low of Rs 1,417.10 so far during the day. The stock hit a 52-week high of Rs 1,911.55 on 9 February 2016. The stock hit a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had outperformed the market over the past 30 days till 22 November 2016, falling 7.59% compared with the 7.87% decline in the Sensex. The scrip had also outperformed the market in past one quarter, falling 7.08% as against Sensexs 7.48% decline.

The large-cap company has equity capital of Rs 90.25 crore. Face value per share is Rs 2.

Lupin announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) to market a generic version of ViiV Healthcare Companys Epzicom Tablets, 600 mg/300 mg.

Lupins Abacavir Sulfate and Lamivudine Tablets, 600 mg/300 mg are the AB rated generic equivalent of ViiV Healthcare Companys Epzicom Tablets, 600 mg/300 mg. Abacavir Sulfate and Lamivudine Tablets, 600 mg/300 mg in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Epzicom Tablets had US sales of $426 million as per IMS MAT September 2016 data.

Lupins consolidated net profit jumped 57.8% to Rs 662.19 crore on 31.9% rise in net sales to Rs 4211.18 crore in Q2 September 2016 over Q2 September 2015.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, central nervous system (CNS), GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Powered by Capital Market - Live News

Gravity grips Sunil Hitech Engineers after bulk deal
Nov 23,2016

Meanwhile, the S&P BSE Sensex was up 64.63 points or 0.25% at 26,025.41

Bulk deal boosted volume on the scrip. On BSE, so far 28.70 lakh shares were traded in the counter as against average daily volume of 2.51 lakh shares in the past one quarter. The stock hit a high of Rs 184 and a low of Rs 166.65 so far during the day. The stock had hit a record high of Rs 468.65 on 20 October 2016. The stock had hit a 52-week low of Rs 155 on 24 June 2016. The stock had underperformed the market over the past 30 days till 22 November 2016, sliding 59.85% compared with the 7.87% decline in the Sensex. The scrip, however, outperformed the market in past one quarter, falling 6.28% as against Sensexs 7.48% decline.

The small-cap company has equity capital of Rs 18.90 crore. Face value per share is Rs 10.

Sunil Hitech Engineers net profit rose 39.74% to Rs 14.84 crore on 19.6% growth in net sales to Rs 496.91 crore in Q2 September 2016 over Q2 September 2015.

Sunil Hitech Engineers is an engineering, procurement & construction (EPC) company.

Powered by Capital Market - Live News

JK Lakshmi Cement gains on bargain hunting
Nov 23,2016

Meanwhile, the BSE Sensex was up 64.85 points, or 0.25%, to 26,025.63.

On BSE, so far 3,735 shares were traded in the counter, compared with average daily volume of 20,864 shares in the past one quarter. The stock hit a high of Rs 364.30 and a low of Rs 347.50 so far during the day. The stock hit a record high of Rs 513.75 on 6 October 2016. The stock hit a 52-week low of Rs 253 on 12 February 2016. The stock had underperformed the market over the past 30 days till 22 November 2016, falling 31.31% compared with the 7.87% decline in the Sensex. The scrip had also underperformed the market in past one quarter, falling 23.22% as against Sensexs 7.48% decline.

The mid-cap company has equity capital of Rs 58.84 crore. Face value per share is Rs 5.

Shares of JK Lakshmi Cement fell 22.44% in seven trading sessions to settle at Rs 347.05 yesterday, 22 November 2016, from its close of Rs 447.45 on 10 November 2016.

JK Lakshmi Cement reported net profit of Rs 24.91 crore in Q2 September 2016 as against net loss of Rs 8.38 crore in Q2 September 2015. Net sales rose 1.52% to Rs 655.57 crore in Q2 September 2016 over Q2 September 2015.

JK Lakshmi Cement manufactures cement, which it sells under the brand name JK Lakshmi.

Powered by Capital Market - Live News

Wockhardt drops after USFDA issues warning letter to C P Pharmaceuticals
Nov 23,2016

The announcement was made during market hours today, 23 November 2016.

Meanwhile, the S&P BSE Sensex was down 46.39 points or 0.18% at 25,914.39

On BSE, so far 2.27 lakh shares were traded in the counter as against average daily volume of 2.93 lakh shares in the past one quarter. The stock hit a high of Rs 685 so far during the day. The stock hit a low of Rs 659 in intraday trade so far, which is 52-week low for the counter. The stock had hit a 52-week high of Rs 1,748.20 on 2 December 2015. The stock had underperformed the market over the past 30 days till 22 November 2016, sliding 22.08% compared with the 7.87% decline in the Sensex. The scrip also underperformed the market in past one quarter, falling 14.13% as against Sensexs 7.48% decline.

The mid-cap company has equity capital of Rs 55.27 crore. Face value per share is Rs 5.

Wockhardt said that currently, there is no business being conducted from C P Pharmaceuticals to the US Market. C P Pharmaceuticals has already initiated required steps to address the concerns raised by US Food and Drug Administration (USFDA) and will be responding to the agency within the prescribed time, Wockhardt said.

Wockhardts consolidated net profit fell 81.59% to Rs 17.02 crore on 10.05% decline in total income to Rs 1084.59 crore in Q2 September 2016 over Q2 September 2015.

Wockhardt is a research based and technology intensive global pharmaceutical and biotechnology company.

Powered by Capital Market - Live News

A2Z Infra Engineering jumps as subsidiary to settle various debts
Nov 23,2016

Meanwhile, the BSE Sensex was down 48.70 points, or 0.19%, to 25,912.08.

On BSE, so far 5.83 lakh shares were traded in the counter, compared with average daily volume of 2.50 lakh shares in the past one quarter. The stock hit a high of Rs 41.40 and a low of Rs 38.60 so far during the day. The stock hit a 52-week high of Rs 51.65 on 1 November 2016. The stock hit a 52-week low of Rs 16.50 on 12 February 2016. The stock had outperformed the market over the past 30 days till 22 November 2016, falling 2.82% compared with the 7.87% decline in the Sensex. The scrip had also outperformed the market in past one quarter, falling 2.82% as against Sensexs 7.48% decline.

The small-cap company has equity capital of Rs 129.62 crore. Face value per share is Rs 10.

A2Z Infra Engineering informed that its subsidiary, A2Z Green Waste Management (A2Z Green), has on 19 November 2016, agreed to a framework with one of its lenders for a settlement of its various debt obligation aggregating to Rs 416.18 crore.

The settlement may include the transfer of two projects of A2Z Green namely: a 500 tonne per day (TPD) of processing and disposal unit for the purposes of municipal solid waste management at Indore city; and a 1500 TPD of P&D unit, collection & transportation facility of municipal solid waste along with 15 megawatts (MW) power plant, located in Kanpur city.

The settlement would be subject to execution of definitive agreement(s) and further subject to various requisite approval(s) of its stake holders including shareholders and lenders as may be required.

Shares of A2Z Infra Engineering surged 12.80% to Rs 37.90 yesterday, 22 November 2016, after the company said that a contract has been awarded to the company by Chhattisgarh State Power Transmission Company for construction of 132 kilovolt S/S Bijapur and associated EHV Line on turnkey basis. The aggregate value of the contract is Rs 41.33 crore. The announcement was made during market hours yesterday, 22 November 2016.

The stock has risen 19.35% in two trading sessions from its close of Rs 33.60 on Monday, 21 November 2016.

A2Z Infra Engineering reported a net loss of Rs 18.75 crore in Q1 June 2016, lower than net loss of Rs 34.21 crore in Q1 June 2015. Net sales surged 148.5% to Rs 202.70 crore in Q1 June 2016 over Q1 June 2015.

A2Z Infra Engineering (formerly known as A2Z Maintenance & Engineering Services) is a fast growing, fully integrated electrical business group (EBG) in India catering to the needs of domestic and international power sector clients in building distribution and transmission infrastructure.

Powered by Capital Market - Live News

JBF Industries weaves strong gains after stellar Q2 results
Nov 23,2016

The result was announced after market hours yesterday, 22 November 2016.

Meanwhile, the S&P BSE Sensex was up 2.79 points, or 0.01%, to 25,963.57

On BSE, so far 16,000 shares were traded in the counter, compared with average daily volume of 29,882 shares in the past one quarter. The stock hit a high of Rs 211.40 and a low of Rs 199 so far during the day. The stock hit a 52-week high of Rs 260.10 on 18 October 2016. The stock hit a 52-week low of Rs 150.10 on 29 February 2016. The stock had underperformed the market over the past 30 days till 22 November 2016, sliding 20.22% compared with the 7.87% decline in the Sensex. The scrip, however, outperformed the market in past one quarter, falling 6.56% as against Sensexs 7.48% decline.

The small-cap company has an equity capital of Rs 81.87 crore. Face value per share is Rs 10.

JBF Industries produces polyester chips for textiles, films and bottles and partially oriented yarn.

Powered by Capital Market - Live News

Sun Pharma gains after acquisition in Russia
Nov 23,2016

The announcement was made before trading hours today, 23 November 2016.

Meanwhile, the BSE Sensex was up 4.56 points, or 0.02%, to 25,965.34.

On BSE, so far 48,000 shares were traded in the counter, compared with average daily volume of 3.49 lakh shares in the past one quarter. The stock hit a high of Rs 696.65 and a low of Rs 691.55 so far during the day. The stock hit a 52-week high of Rs 898 on 23 February 2016. The stock hit a 52-week low of Rs 572.40 on 9 November 2016. The stock had outperformed the market over the past 30 days till 22 November 2016, falling 7.68% compared with the 7.87% decline in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 10.50% as against Sensexs 7.48% decline.

The large-cap company has equity capital of Rs 240.68 crore. Face value per share is Re 1.

Sun Pharmaceutical Industries (Sun Pharma) announced the execution of definitive agreements by its wholly owned subsidiary, for the acquisition of 85.1% of JSC Biosintez, a Russian pharmaceutical company engaged in manufacture and marketing of pharmaceutical products in Russia and CIS region. The equity consideration for the 85.1% stake is $24 million. Sun Pharma would also assume a debt of approximately $36 million as part of this transaction. Biosintez is a Russian pharmaceutical company focusing on the hospital segment with annual revenues of approximately $52 million for 2015. It has a manufacturing facility in Penza region with capabilities to manufacture a wide variety of dosage forms including pharmaceuticals for injections, blood substitutes, blood preservatives, ampoules, tablets, ointment, creams, gels, suppositories, active pharmaceutical ingredients (APIs), etc.

The transaction, expected to be completed by end of 2016, is subject to approval of the Russian Federal AntiMonopoly Service and other closing conditions. As per IMS (MAT September 2016), the Russian pharmaceutical market recorded sales of approximately $10 billion. The market recorded a growth of 7.4% in local currency terms as per IMS.

In a separate announcement after market hours yesterday, 22 November 2016, Sun Pharma said it received a letter from the Chief Financial Officer (CFO), Uday Baldota that he would be tendering his resignation as the CFO of Sun Pharmaceutical Industries to be effective with effect from in and around April 2017 due to his shifting to United States of America in and around April 2017 to look after the business of Taro Pharmaceutical Industries, a subsidiary of Sun Pharmaceutical Industries as its Chief Executive Officer.

On a consolidated basis, Sun Pharmaceutical Industries net profit surged 117.25% to Rs 2235.14 crore on 13.21% rise in net sales to Rs 7764.03 crore in Q2 September 2016 over Q2 September 2015.

Sun Pharmaceutical Industries is the worlds fifth largest specialty generic pharmaceutical company and Indias top pharmaceutical company.

Powered by Capital Market - Live News

Bharti Airtel gains after completing acquisition of rights to use spectrum for AP circle
Nov 23,2016

The announcement was made after market hours yesterday, 22 November 2016.

Meanwhile, the S&P BSE Sensex was up 55.66 points or 0.21% at 26,016.44

On BSE, so far 15,000 shares were traded in the counter as against average daily volume of 3.14 lakh shares in the past one quarter. The stock hit a high of Rs 308 and a low of Rs 304 so far during the day. The stock had hit a 52-week high of Rs 384.90 on 28 April 2016. The stock had hit a 52-week low of Rs 282.30 on 29 January 2016. The stock had outperformed the market over the past 30 days till 22 November 2016, falling 0.8% compared with the 7.87% decline in the Sensex. The scrip, however, underrperformed the market in past one quarter, sliding 13.77% as against Sensexs 7.48% decline.

The large-cap company has equity capital of Rs 1998.70 crore. Face value per share is Rs 5.

Bharti Airtel announced that it has successfully completed the acquisition of rights to use 20 MHz of spectrum in 2300 Band ( BWA) from Aircel, for Andhra Pradesh circle following the receipt of all necessary approvals and satisfying all the conditions (including conditions stated in the Spectrum Trading Guidelines). With this, Bharti Airtel has completed the transaction in all 8 telecom circles, the company said.

On a consolidated basis, Bharti Airtels net profit fell 4.9% to Rs 1460.70 crore on 3.4% growth in net sales to Rs 24651.50 crore in Q2 September 2016 over Q2 September 2015.

Bharti Airtel is a leading global telecommunications company with operations in 18 countries across Asia and Africa.

Powered by Capital Market - Live News

L&T gains after strong Q2 results
Nov 23,2016

The result was announced after market hours yesterday, 22 November 2016.

Meanwhile, the BSE Sensex was up 74.94 points, or 0.29%, to 26,035.72.

On BSE, so far 21,000 shares were traded in the counter, compared with average daily volume of 2.57 lakh shares in the past one quarter. The stock hit a high of Rs 1,374.40 and a low of Rs 1,353 so far during the day. The stock hit a 52-week high of Rs 1,615 on 27 July 2016. The stock hit a 52-week low of Rs 1,016.60 on 12 February 2016. The stock had underperformed the market over the past 30 days till 22 November 2016, falling 11.06% compared with the 7.87% decline in the Sensex. The scrip had also underperformed the market in past one quarter, sliding 9.76% as against Sensexs 7.48% decline.

The large-cap engineering & construction major has equity capital of Rs 186.47 crore. Face value per share is Rs 2.

The companys consolidated profit after tax (PAT) before exceptional items rose 41% to Rs 1032 crore in Q2 September 2016 over Q2 September 2015. As a part of implementation of its strategic plan, the company has divested the General Insurance business. Gross revenue on consolidated basis rose 8.2% to Rs 25011 crore in Q2 September 2016 over Q2 September 2015. Consolidated order inflow increased by 11% year on year (YoY) to Rs 31119 crore in Q2 September 2016. International orders constituted 24% of the total order inflow. Consolidated order book stood at Rs 251773 crore as on 30 September 2016, higher by 4% on YoY basis. International order book constituted 29% of the total order book.

On the business outlook, L&T said, it has integrated range of comprehensive offerings in its various operating segments and is implementing its strategic plan of profitable growth and higher return on equity. On the international front, the company continues to strengthen its position and pursue select prospects in the core infrastructure and energy sector. L&T said, it is well placed to benefit from the emerging opportunities and sustain its leadership position across the sectors.

L&T is a major Indian multinational engaged in technology, engineering, construction, manufacturing and financial services. It operates in more than 30 countries worldwide.

Powered by Capital Market - Live News

DHFL gains after bargain hunting
Nov 22,2016

Meanwhile, the S&P BSE Sensex was up 204.48 points, or 0.79%, to 25,969.62

On BSE, so far 2.97 lakh shares were traded in the counter, compared with average daily volume of 3.34 lakh shares in the past one quarter. The stock hit a high of Rs 228.10 and a low of Rs 220 so far during the day. The stock hit a record high of Rs 337 on 20 October 2016. The stock hit a 52-week low of Rs 140.55 on 12 February 2016. The stock had underperformed the market over the past 30 days till 21 November 2016, sliding 33.89% compared with the 8.23% decline in the Sensex. The scrip also underperformed the market in past one quarter, declining 19.42% as against Sensexs 7.95% decline.

The mid-cap company has an equity capital of Rs 313.13 crore. Face value per share is Rs 10.

Dewan Housing Finance Corporations net profit rose 28.96% to Rs 232.61 crore on 19.65% rise in total income to Rs 2167.72 crore in Q2 September 2016 over Q2 September 2015.

Dewan Housing Finance Corporation provides loans for purchase or construction of residential houses.

Powered by Capital Market - Live News

IRB Infra slips after weak Q2 results
Nov 22,2016

The result was announced during trading hours today, 22 November 2016.

Meanwhile, the BSE Sensex was up 157.87 points, or 0.61%, to 25,923.01.

On BSE, so far 4.40 lakh shares were traded in the counter, compared with average daily volume of 3.53 lakh shares in the past one quarter. The stock hit a high of Rs 194.15 and a low of Rs 178.20 so far during the day. The stock hit a 52-week high of Rs 269.30 on 4 January 2016. The stock hit a 52-week low of Rs 178.20 on 22 November 2016. The stock had underperformed the market over the past 30 days till 21 November 2016, falling 23.66% compared with the 8.23% decline in the Sensex. The scrip had also underperformed the market in past one quarter, falling 19.24% as against Sensexs 7.95% decline.

The mid-cap company has equity capital of Rs 351.45 crore. Face value per share is Rs 10.

IRB Infrastructure Developers is an integrated infrastructure development and construction company with significant experience in toll roads and highways sector.

Powered by Capital Market - Live News

A2Z Infra spurts on new order win
Nov 22,2016

The announcement was made during market hours today, 22 November 2016.

Meanwhile, the S&P BSE Sensex was up 175.01 points or 0.68% at 25,940.15

On BSE, so far 1.75 lakh shares were traded in the counter as against average daily volume of 2.48 lakh shares in the past one quarter. The stock hit a high of Rs 35.85 and a low of Rs 33.10 so far during the day. The stock had hit a 52-week high of Rs 51.65 on 1 November 2016. The stock had hit a 52-week low of Rs 16.50 on 12 February 2016.

The small-cap company has equity capital of Rs 129.62 crore. Face value per share is Rs 10.

A2Z Infra Engineering said that a contract has been awarded to the company by Chhattisgarh State Power Transmission Company for construction of 132 kilovolt S/S Bijapur and associated EHV Line on turnkey basis. The aggregate value of the contract is Rs 41.33 crore.

A2Z Infra Engineering reported a net loss of Rs 18.75 crore in Q1 June 2016, lower than net loss of Rs 34.21 crore in Q1 June 2015. Net sales surged 148.5% to Rs 202.70 crore in Q1 June 2016 over Q1 June 2015.

A2Z Infra Engineering (formerly known as A2Z Maintenance & Engineering Services) is a fast growing, fully integrated electrical business group (EBG) in India catering to the needs of domestic and international power sector clients in building distribution and transmission infrastructure.

Powered by Capital Market - Live News

Vedanta gains after board OKs fund raising
Nov 22,2016

The announcement was made during market hours today, 22 November 2016.

Meanwhile, the BSE Sensex was up 154.12 points, or 0.60%, to 25,919.26.

On BSE, so far 8.18 lakh shares were traded in the counter, compared with average daily volume of 11.33 lakh shares in the past one quarter. The stock hit a high of Rs 206.20 and a low of Rs 199.10 so far during the day. The stock hit a 52-week high of Rs 233.65 on 10 November 2016. The stock hit a 52-week low of Rs 58.10 on 12 February 2016. The stock had outperformed the market over the past 30 days till 21 November 2016, falling 3.10% compared with the 8.23% decline in the Sensex. The scrip had also outperformed the market in past one quarter, rising 13.15% as against Sensexs 7.95% decline.

The large-cap company has equity capital of Rs 296.47 crore. Face value per share is Re 1.

Vedanta announced that it has received boards approval to raise Rs 300 crore through issue of 3,000 secured redeemable non-cumulative non-convertible debentures (NCDs) of face value of Rs 10 lakh each. The tenure of the NCDs is three years and five months from the date of allotment, while date of maturity is 22 April 2020. Crisil has assigned AA-/Stable rating to the said instrument.

In a separate announcement today, 22 November 2016, the company said that the board has approved the appointment of chief financial officer Arjun Kumar GR as a whole-time director of the company and Bhumika Sood as company secretary. The appointments reflect the focus of Vedanta towards empowering its professionals and developing in-house talent, said, Tom Albanese, CEO, Vedanta.

On a consolidated basis, Vedantas net profit rose 17.14% to Rs 1252.13 crore on 4.13% decline in net sales to Rs 15665.64 crore in Q2 September 2016 over Q2 September 2015.

Vedanta is a diversified natural resources company, whose business primarily involves producing oil & gas, zinc - lead - silver, copper, iron ore, aluminium and commercial power. The company has a presence across India, South Africa, Namibia, Australia and Ireland.

Powered by Capital Market - Live News